BioRestorative Therapies, Inc. BRTX 深 滬
等待開盤 03-26 09:30:00 美东时间
0.31
+0.017
+5.77%
華盛通- 最 高0.3217
- 今 開0.2931
- 成交量 224.60万股
- 最 低 0.2931
- 昨 收 0.2931
- 總市值 718.02万
- 52周最高 2.045
- 市盈率 靜 --
- 換手率 9.70%
- 52周最低 0.19
- 委 比 -57.45%
- 總股本 2316.20万
- 歷史最高 8.90
- 量 比 0.66
- 振 幅 9.76%
- 歷史最低 0.19
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioRestorative Therapies To Present Data On ~45 Participants From Its Phase 2 Clinical Study Of Hypoxic-cultured Mesenchymal Stem Cells To Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that new
03-19 20:09
Why Zevra Therapeutics Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA, SOAR, MTEN, MDCX, NXGL, ABTC, and VALN. Losers include GSIW, POM, ARQ, RAIL, and NTZ.
03-10 16:42
BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy
BioRestorative Therapies在2026年第一季度取得多项重要进展，包括完成其领先的临床项目BRTX-100的II期试验患者招募，获得积极的FDA Type B会议结果以及500万美元的公开募股。这些进展强化了其商业运营的发展势头。
03-04 13:00
BioRestorative Therapies Secures Australian Patent Allowance For 3D Brown Adipose-Derived Stem Cell Aggregates
GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic
02-24 21:34
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
<p>MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (NASDAQ: BRTX) has been granted a patent in Australia for its ThermoStem® technology, designed to treat obesity and metabolic disorders. The patent covers methods for creating non-naturally occurring 3D brown adipose-derived stem cell aggregates, offering a potential alternative to GLP-1 drugs. CEO Lance Alstodt highlighted the company's commitment to advancing ce...
02-24 13:30
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers CytoMed Therapeutics (NASDAQ:GDTC) shares moved upwards by 6.9% to $1....
02-14 05:06
BioRestorative Announces Pricing of $5.0 Million Public Offering
BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced a public offering of 14,285,715 shares of common stock and warrants, priced at $0.35 per share, with total proceeds of approximately $5.0 million. The funds will be used for clinical trials of BRTX-100, preclinical research of the ThermoStem Program, development of a commercial biocosmeceuticals platform, and general corporate purposes.
02-12 03:30
Why Credo Technology Group Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Shares of Credo Technology Group Holding Ltd (NASDAQ:CRDO) rose sharply in pre-...
02-10 17:45
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. has completed enrollment in its Phase 2 clinical trial evaluating BRTX-100, an autologous mesenchymal stem cell therapy, for the treatment of chronic lumbar disc disease (cLDD). The trial, which enrolled 99 participants across 15 U.S. sites, is the largest FDA-authorized Phase 2 cell therapy trial for cLDD and follows a prospective, randomized, double-blind, sham-controlled design. The primary endpoints are safety (...
02-10 13:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock rose 10.2% to $2.8 during Wedn...
2025-11-20 05:07
